Navigation Links
Jennerex Announces Presentations at Upcoming Conferences
Date:12/23/2009

SAN FRANCISCO, Dec. 23 /PRNewswire/ -- Jennerex Biotherapeutics, a clinical-stage biotherapeutics company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced that management will present at the following upcoming investor conferences.


    Biotech Showcase 2010
    Tuesday, January 12, 2010
    9:40 a.m. PT
    Marines' Memorial Club and Hotel, San Francisco

    OneMedForum 2010
    Wednesday, January 13, 2010
    2:40 p.m. PT
    Sir Francis Drake Hotel, San Francisco

About Jennerex

Jennerex is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594, currently in an international randomized Phase 2 clinical trial for patients with primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the Company's poxviruses in cancer cells. These products not only cause cancer cell lysis thereby killing through replication, they simultaneously shut-off the blood supply to tumors, as well as stimulating the body's immune response to the cancer. Jennerex, Inc. is headquartered in San Francisco and has manufacturing and research activities based at the Ottawa Hospital Research Institute in Ottawa, Canada. For more information about Jennerex and the Company's pipeline of three clinical-stage products, please visit www.jennerex.com .

SOURCE Jennerex Biotherapeutics


'/>"/>
SOURCE Jennerex Biotherapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
2. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
3. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
6. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
7. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
8. Macomb County Announces Final 2009 H1N1 Clinic
9. Access MediQuip Announces Release of Partners in Focus Provider Portal
10. Unilens Announces Extraordinary Meeting Results
11. Arrayit Corporation Announces Manufacturing Breakthrough
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... WARSAW, Ind. , April 20, 2017  Zimmer ... leader in musculoskeletal healthcare, today announced that it will ... Health Care Conference at the InterContinental Hotel in ... 2017.  Zimmer Biomet will present at 11:20 a.m. Eastern ... can be accessed via Zimmer Biomet,s Investor Relations website ...
(Date:4/20/2017)... , April 20, 2017  CVS Pharmacy, ... today unveiled a new store design to enhance ... of healthier food, health-focused products and expanded beauty ... to help customers discover new offerings. Together with ... next evolution of the customer experience at CVS ...
(Date:4/20/2017)... Eyevensys, a private biotechnology company ... expression technology that enables the safe, local, sustained production ... wide range of ophthalmic diseases, announces it has received ... Agency (MHRA) to advance its technology into clinical development. ... The EyeCET ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... Labs often ... it difficult for lab operators and management to assess these processes with a ... wasteful or unnecessary actions. , Created with the help of both internal ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... “Learning to ... to navigate life. “Learning to Use Your SPIRITUAL COMPASS To Navigate Life Issues” ... for various nonprofits, former Chairman of the Board of Directors for CONTACT USA, and ...
(Date:4/24/2017)... ... April 24, 2017 , ... Insect ... distributors and International relief organizations across the globe to provide effective protection against ... and work wear collections via insectshield.com . In the wake of the ...
(Date:4/23/2017)... ... April 23, 2017 , ... ... services announced the achievement of Cisco Select certification and SMB specialization. Altura ... States. , In earning the Select Certification, Altura fulfilled the training ...
(Date:4/22/2017)... ... April 22, 2017 , ... Brian Emmer brings more ... Sales and Business Development at OAKWORKS, Inc. Mr. Emmer is responsible for ... strategic planning for the company. Recognized industry-wide as a healthcare innovator, Emmer ...
Breaking Medicine News(10 mins):